The present invention generally relates to systems and methods for monitoring and/or providing feedback for drugs or other pharmaceuticals taken by a subject. In one aspect, the present invention is directed to devices and methods for determining a species within the skin of a subject; and producing feedback to a subject based on the determination of the species. The feedback may be, for example, visual, audible, tactile, a change in temperature, etc. In some cases, information regarding the determination of the species may be transmitted to another entity, e.g., a health care provider, a computer, a relative, etc., which may then provide feedback to the subject in some fashion. In some cases, the feedback may be directly indicative of the species, e.g., whether the species is present, the concentration of the species, whether a by-product of a reaction involving the species is present, whether a compound affected by the species is present, etc. However, the feedback may also be indirect in some embodiments. For example, the subject may be presented with an external reward, e.g., based on the determination of the species within the skin. For instance, a reward such as cash, coupons, songs, discounts, personal items, etc., may be offered based on the level of compliance of the subject. Still other aspects of the invention are generally directed to kits involving such devices (with or without the drug to be monitored), methods of promoting such systems, or the like.

Systems and methods for processing magnetic resonance imaging (MRI) data are provided. A method includes receiving MRI data comprising a plurality of k-space points and deriving a plurality of image data sets based on the MRI data, each of the plurality of MRI image sets obtained by zeroing a different one of the plurality of k-space points. The method further includes computing image space metric values for each of the plurality of image data sets and adjusting a portion of the MRI data associated with ones of the image space metric values that fail to meet a threshold value to yield adjusted MRI data.

A region growing algorithm for controlling leakage is presented including a processor configured to select a starting point for segmentation of data, initiate a propagation process by designating adjacent voxels around the starting point, determine whether any new voxels are segmented, count and analyze the segmented new voxels to determine leakage levels, and identify and record segmented new voxels from a previous iteration when the leakage levels exceed a predetermined threshold. The processor is further configured to perform labeling of the segmented new voxels of the previous iteration, select the segmented new voxels from the previous iteration when the leakage levels fall below the predetermined threshold, and create a voxel list based on acceptable segmented voxels found in the previous iteration.

The disclosed embodiments relate to pulse oximetry. An exemplary pulse oximeter comprises a probe that is adapted to be attached to a body part of a patient to create a signal indicative of an oxygen saturation of blood of the patient, and a processor that is adapted to receive the signal produced by the probe, to calculate an SPO2 value based on the signal, to detect a plurality of pattern types of SPO2 indicative of pathophysiologic events, and to produce an output indicative of a detected one of the plurality of pattern types.

An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.

The present application provides Ag/AgCl based reference electrodes having an extended lifetime that are suitable for use in long term amperometric sensors. Electrochemical sensors equipped with reference electrodes described herein demonstrate considerable stability and extended lifetime in a variety of conditions.

MRI compatible localization and/or guidance systems for facilitating placement of an interventional therapy and/or device in vivo include: (a) a mount adapted for fixation to a patient; (b) a targeting cannula with a lumen configured to attach to the mount so as to be able to controllably translate in at least three dimensions; and (c) an elongate probe configured to snugly slidably advance and retract in the targeting cannula lumen, the elongate probe comprising at least one of a stimulation or recording electrode. In operation, the targeting cannula can be aligned with a first trajectory and positionally adjusted to provide a desired internal access path to a target location with a corresponding trajectory for the elongate probe. Automated systems for determining an MR scan plane associated with a trajectory and for determining mount adjustments are also described.

A magnetic resonance imaging apparatus includes an acoustic control unit and an image data acquisition unit. The acoustic control unit applies a gradient magnetic field for controlling a sound in synchronization with a signal representing a respiratory body motion. The image data acquisition unit acquires imaging data by subsequently imaging to control the sound and generate image data based on the imaging data.

A three dimensional imaging system includes a first laser emitting light at a first wavelength, and a scanner for scanning the laser light in a pattern on the target area. A photo detector receives light reflected from the target area as a contrasted vein image, resulting from differential absorption and reflection therein of the first wavelength of light. The intensity of the first laser is incrementally increased, and the photo detector thereby receives a plurality of contrasted vein images, each being at incrementally distinct depths beneath the target skin surface. Image processing is performed on the plurality of vein images to successively layer the veins in the images according to their depth, to create a single processed vein image. A second laser emitting a second wavelength of light is used in combination with the scanner to project the processed vein image onto the target area to overlay the veins therein.

A device for fluorescence-based imaging and monitoring of a target comprising: a light source emitting light for illuminating the target, the emitted light including at least one wavelength or wavelength band causing at least one biomarker associated with the target to fluoresce; and a light detector for detecting the fluorescence.

The present invention has an object to measure lymphatic pressure with more safety and ease at lower cost. To achieve this, a lymphatic pressure-measuring system 1 includes: a manchette 11 fitted on a vital observation portion; a measurement unit 13 that measures and outputs pressure of the manchette 11; an infrared camera 21 that detects fluorescence emitted from fluorescent dye previously injected into a lymph vessel in the vital observation portion; and an image processing device 22 that generates and displays an image showing a position of the fluorescent dye in the lymph vessel based on a detection result of the infrared camera 21. The infrared camera 21 repeats the detection while the pressure of the manchette 11 decreases from first pressure to block a lymph flow in the vital observation portion to second pressure at restart of the lymph flow. The measurement unit 13 repeats the measurement during the period.

A device for detecting a cardiac event is disclosed. Detection of an event is based on a test applied to a parameter whose value varies according to heart rate. Both the parameter value and heart rate (RR interval) are filtered with an exponential average filter. From these filtered values, the average change in the parameter and the RR interval are also computed with an exponential average filter. Before computing the average change in the parameter, large changes in the parameter over short times, which may be caused by body position shifts, are attenuated are removed, so that the average change represents an average of small/smooth changes in the parameter's value that are characteristic of acute ischemia, one of the cardiac events that may be detected. The test to detect the cardiac event depends on the heart rate, the difference between the parameter's value and its upper and lower normal values, and its average change over time, adjusted for heart rate changes. The upper and lower normal parameter values as a function of heart rate are determined from long term stored data of the filtered RR values and parameter values. Hysteeresis related data and transitory deviations from normal (e.g. vasospasm related data) are excluded from the computation of normal upper and lower parameter bounds.

A system for facilitating remote medical diagnosis and consultation of heart disease for a patient, the system comprising: a diagnostic device for performing Electrocardiography on the patient, a network device in communication with the diagnostic device via wired or wireless communication links, a software program pre-installed in the network device, a server located remotely, wherein during operation, the patient activates the diagnostic device which will perform Electrocardiography on the patient, the diagnostic device receives diagnostic data and transmits the diagnostic data to the network device, the software program transmit the diagnostic data to over a network to a server which a physician have access to, and based on the diagnostic data gathered by the server and some additional medical data, the physician can review the patient's health condition and offer an appropriate feedback and diagnosis for the patient.

A biometric monitoring device measuring various biometric information is provided that allows the person to take and/or display a heart rate reading by a simple user interaction with the device, e.g., by simply touching a heart rate sensor surface area or moving the device in a defined motion pattern. Some embodiments of this disclosure provide biometric monitoring devices that allow a person to get a quick heart rate reading without removing the device or interrupting their other activities. Some embodiments provide heart rate monitoring with other desirable features such as feedback on data acquisition status.

A peak-relevant value device acquires a peak-relevant value (for example, the peak value of an R wave (R peak value)) every cycle from an electrocardiogram acquired. The frequencies of the peak-relevant value acquired as time-series data and the magnitudes for the respective frequencies are analyzed. A peak-relevant value LF calculating device calculates an LF component (peak-relevant value LF component) from the frequency component of the peak-relevant value. An interval acquiring device acquires the interval between characteristic points of the electrocardiographic complex from the electrocardiogram acquired and the frequencies of the feature point interval acquired as time-series data to acquire the magnitudes of the respective frequency component are analyzed. An interval HF calculating device calculates the HF component from the frequency components of the feature point interval acquired and pain is judged on the basis of the variations of the peak-relevant value LF components and the interval HF components.

A method and system for treating brain disorders comprises detecting activity of a first target area of the brain via a first implanted sensor and determining the presence of target brain activity by analyzing the detected brain activity in combination with treating the user based upon the determined presence of target brain activity by supplying a first therapeutic agent to the first target area via a first implanted fluid delivery member including at least one distal opening adjacent to the first target area. In addition, the system may be used as well for testing the effectiveness of drugs.

A device and method for accurately characterizing tissue impedance employs multiple electrodes at a plurality of separation distances to cancel the effects of front end loading leakage currents and electrode polarization to improve the accuracy of sensitive impedance measurements used to identify cancerous tissues. These measurements may be automated over a range of frequencies.

A device is described for measuring electrical characteristics of biological tissues with one or a plurality of electrodes and a processor controlling the stimulation and measurement in order to detect the presence of abnormal tissue masses in the breast and determine probability of tumors containing malignant cancer cells being present in a breast. The device has the capability of providing the location of the abnormality, at least to the quadrant. Either single or multiple source electrodes can be used. Either palpable lumps can be evaluated or screening or breasts, whether with palpable masses or not, can be accomplished. The method for measuring electrical characteristics includes placing electrodes and applying a voltage waveform in conjunction with a current detector. A mathematical analysis method is then applied to the collected data, which computes spectrum of frequencies and correlates magnitudes and phases with given algebraic conditions to determine mass presence and type.

An information processing method includes the following steps: applying a pattern matching process on the body motion signal information, and extracting rhythm cycle candidate waves which are rhythm cycle candidates related to the rhythmic motion; performing −1 or more times integration on the body motion signal information to obtain a motion trajectory, and performing coarse-graining on the motion trajectory to produce an auxiliary wave; superimposing the rhythm cycle candidate waves which are extracted in the process of extracting the cycle candidate waves, on the obtained auxiliary wave, and selecting a cycle of a rhythm cycle candidate wave which has a peak in the auxiliary wave, as a true cycle; and finally obtaining a result of the processing.

Transcranial magnetic stimulation (TMS) is a remarkable tool for probing the brain. However, it is still unclear why specific regions in the cortex are excitable by TMS while others are not. This invention provides methods and tools for the design of efficient magnetic stimulators. Such stimulators can excite neuronal networks that were not sensitive to stimulation until now. Stimulation can be carried out both in-vitro and in-vivo. Novel systems and techniques of this invention will enable both treatment and diagnostics by stimulating regions of the brain or neuronal assemblies that were previously unaffected by TMS.

In aspects of the present disclosure, an auto turn on blood glucose monitoring unit including a calibration unit integrated with one or more components of an analyte monitoring system is provided. Also disclosed are methods, systems, devices and kits for providing the same.

An apparatus and method for indicating locus of an ultrasonic probe configured to transmit and receive ultrasonic waves toward a part of a subject wherein a position or movement of the ultrasonic probe is detected, and a locus of the ultrasonic probe on an image of the part of the subject is indicated according to the detected position or movement.

Apparatus and methods are described including acquiring a first set of extraluminal images of a lumen, using an extraluminal imaging device. At least one of the first set of images is designated as a roadmap image. While an endoluminal device is being moved through the lumen, a second set of extraluminal images is acquired. A plurality of features that are visible within images belonging to the second set of extraluminal images are identified. In response to the identified features in the images belonging to the second set of extraluminal images, a plurality of local calibration factors associated with respective portions of the roadmap image are determined. Other applications are also described.

The invention relates to improved process for the preparation of fesoterodine and its pharmaceutically acceptable salt, specifically fesoterodine fumarate of formula (1). The invention relates to solid state forms of a novel salt of fesoterodine and process for the preparation thereof. The invention also relates to highly pure fesoterodine fumarate substantially free of impurity X at RRT 1.37. The invention also provides solid particles of pure fesoterodine fumarate wherein 90 volume-percent of the particles (D90) have a size of higher than 200 microns.

A method for continuously preparing a carboxylic acid ester is disclosed. In the method of the present invention, a vertical reactor is filled with a solid catalyst, a carboxylic acid and an alcohol are introduced into a lower part of the vertical reactor, esterification is performed to form an esterized mixture, the esterized mixture is output from an upper part of the vertical reactor, and distillation is performed to isolate the carboxylic acid ester. The method of the present invention is simple, easily controlled and environmental friendly, and has significantly high conversion rate and selectivity.

A chemically amplified resist composition comprising a base polymer and an amine quencher in the form of a β-alanine, γ-aminobutyric acid, 5-aminovaleric acid, 6-aminocaproic acid, 7-aminoheptanoic acid. 8-aminooctanoic acid or 9-aminononanoic acid derivative having an unsubstituted carboxyl group has a high contrast of alkaline dissolution in rate before and after exposure and forms a pattern of good profile at a high resolution, minimal roughness and wide DOF.

A negative pattern is formed by coating a resist composition comprising a polymer comprising recurring units having a tertiary ester type acid labile group having a plurality of methyl or ethyl groups on alicycle and an acid generator onto a substrate, prebaking, exposing to high-energy radiation, baking, and developing in an organic solvent developer so that the unexposed region of resist film is dissolved away and the exposed region of resist film is not dissolved. The resist composition exhibits a high dissolution contrast during organic solvent development and forms a fine hole or trench pattern of dimensional uniformity.

A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided.

The subject of the present invention are novel esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them and their use in the production of drugs for the prophylaxis or treatment of oncogenic diseases and diseases connected with increased cell proliferation.

The present invention provides drug conjugates comprising 5-aminolevulinic acid (ALA), an aldehyde and a carboxylic acid that may function as a histone deacetylase inhibitor (HDACI). These conjugates may serve as co-drugs which release a plurality of active species in vivo. The novel drug conjugates may be used, for the treatment or prevention of cancer in PDT-dependent and/or PDT-independent (nonPDT) treatments, as well as for cosmetic uses. In addition the present invention provides novel uses for both the novel and known compounds. According to some embodiments, the present invention provides drug conjugates (co-drugs) comprising (i) ALA, (ii) an aldehyde and (iii) a carboxylic acid that may function as a histone deacetylase inhibitor (HDACO for the treatment of anemia and/or for the induction of erythropoiesis.

The invention relates to a process for preparing pentabromobenzyl acrylate through the reaction of pentahalobenzyl halide with a salt of acrylic acid in water-immiscible solvent, wherein said salt is in aqueous form and the reaction is carried out in the presence of a phase transfer catalyst. A process for polymerizing the pentabromobenzyl acrylate in halogenated aromatic solvent and the poly (pentabromobenzyl acrylate) obtained are also disclosed.

The present invention relates to a process for synthesizing a multifunctional compound, including the reaction of a compound of formula (II) with atmospheric or molecular oxygen, in the presence of at least one aldehyde of formula (III), and optionally in the presence of at least one catalyst or at least one radical initiator; wherein: R10, R20, R30, R40, R50, L2, R60, R7, R8, and R9 are as described in the claims. The invention also relates to the use of these compounds as monomers for the preparation of polyurethane. The invention also relates to the use of these compounds as monomers of polymers or of biopolymers.

The invention relates to the production of 2-octylacrylate of high purity and in good yield using ethyl titanate in solution in 2-octanol or 2-octyl titanate as a transesterification catalyst.

A resist composition which can form a very fine resist pattern with excellent lithography properties, a new polymeric compound useful for the resist composition, and a compound useful as a monomer for the polymeric compound. The resist composition contains a polymeric compound containing a structural unit (a0) represented by general formula (a0) shown below. In the formula (a0), A is an anion represented by the general formula (1) or (2).

A method of labeling a sulfenic acid (—SOH) group of a cysteine residue in a protein; or peptide, comprises contacting said protein or peptide with a beta-ketoester to covalently couple said beta-ketoester to said cysteine residue and form a beta-ketoester-labeled cysteine residue in said protein or peptide.

A polyimide demonstrates low coefficient of hygroscopic expansion and low water absorption coefficient when used as an insulation film. The polyimide is derived from a tetracarboxylic acid dianhydride containing ester group expressed by the general formula below, and a polyester imide precursor: wherein R is independent and represents a straight or branched-chain alkyl group with 1 to 6 carbon atoms or straight or branched-chain alkoxyl group with 1 to 6 carbon atoms, n is an integer of 0 to 4, and m is an integer of 2 to 4, but wherein, if m =2, n is an integer of 1 to 4.

Acetaminophen conjugates are provided, which have an acetaminophen moiety covalently linked to a second moiety. The conjugates provided may have one or more advantageous properties, including increased water solubility as compared to acetaminophen, reduced toxicity profile as compared to acetaminophen and an altered pharmacokinetic profile. Formulations comprising the conjugates are also provided, as are methods of using the conjugates and kits comprising the conjugates.

Aromatic isocyanates are produced by reacting one or more aromatic primary amines with phosgene in the gas phase. The phosgene and primary aromatic amine(s) are reacted at a temperature above the boiling temperature of the amine(s) in a reactor having a reaction space which is essentially rotationally symmetric to the direction of flow. The flow fate, averaged over the cross-section, of the reaction mixture along the axis of the essentially rotationally symmetric reaction space in the section of the reaction space in which the conversion of the amine groups into isocyanate groups is between 4 and 80% is not more than 8 m/sec. The flow rate averaged over the cross-section of the reaction mixture along the axis of the essentially rotationally symmetric reaction space in the section of the reaction space in which the conversion of the amine groups into isocyanate groups is 4 to 80% is always below the flow rate averaged over the cross-section at the start of this section.

A compound of Formula (I): or a pharmaceutically acceptable salt of the compound. Also described are pharmaceutical formulations thereof and methods of using the same.

Provided is a method for producing a chlorogenic acids composition having a reduced caffeine content and good taste and favor, capable of efficiently recovering high purity of chlorogenic acids from a chlorogenic acids-containing composition. The method for producing a purified chlorogenic acids composition comprises a step A of bringing a chlorogenic acids-containing composition into contact with a cation exchange resin; a step B of bringing the liquid obtained in the step A into contact with an anion exchange resin; and a step C of bringing an eluent into contact with the anion exchange resin after the step B.

A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a composition for muscle relaxation containing the phenyl alkyl carbamate derivative compounds and/or pharmaceutically acceptable salt thereof as an active ingredient, and a method of muscle relaxation comprising administering a pharmaceutically effective amount of the phenyl alkyl carbamate derivative compound and/or a pharmaceutically acceptable salt thereof to a subject in need of to a subject in need of, are provided.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

Provided is a gem-dinitro ester compound, represented by Formula 1 below: wherein R is a substituted or unsubstituted straight-chain or side-chain alkyl group of C2˜C12.

Isocyanates are produced in the gas phase and by-products such as ammonium halides are selectively separated from the gas phase by desublimation.

The present invention relates to a method for working up distillation, residues from isocyanate production in which monomeric isocyanate present in distillation residues is recovered by means of a spray-dry method and the overall yield of monomeric isocyanate is thus significantly increased.

The present invention provides aryl ketone compounds and compositions containing them which facilitate the delivery of active agents. The aryl ketone compounds have the formula or a salt thereof, where n=1 to 9, and R1 to R5 are independently hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, C2 to C4 alkenyl, halogen, hydroxyl, —NH—C(O)—CH3, or —O—C6H5.

The present invention relates to a covalently organo-modified LDH (LDH/APTES) was found to be an efficient and reusable heterogeneous catalyst for C—C bond forming reactions (i.e. Aldol condensation, Knoevenagel condensation, Henry reaction, Michael addition). More particularly, this catalyst shows consistent activity for several cycles in C—C bond forming reaction. These catalysts were successfully characterized by XRD, FT-IR, 29Si CP MAS NMR.

An object of the present invention is to improve the stability of an ethylenically unsaturated compound having an isocyanate group in the molecule by preventing a polymerization of the ethylenically unsaturated compound. The present invention relates to a stabilizing composition for an isocyanate group-containing ethylenically unsaturated compound, comprising: an isocyanate group-containing ethylenically unsaturated compound (A) which comprises one or more isocyanate groups and one or more ethylenically unsaturated groups in the molecule; and a stabilizing agent (B) which is a compound in which at least one of the ethylenically unsaturated groups in the compound (A) is replaced with an alkyl group which may have a substituent.

Chiral amino compounds, methods of preparation and uses thereof. Tamiflu can be obtained from the said compounds. Multi-substituted chiral tetrahydropyrrolyl amine which can be used as intermediate compounds of medicament can also be produced by the said compounds.

A catalytic process for dehydration of an aliphatic C2-C6 alcohol to its corresponding olefin is disclosed. The process continuously flows through a reaction zone a liquid phase containing an aliphatic C2-C6 alcohol to contact a non-volatile acid catalyst at a reaction temperature and pressure to at least partially convert the aliphatic C2-C6 alcohol in the liquid phase to its corresponding olefin. The reaction pressure is greater than atmospheric pressure and the reaction temperature is above the boiling point of the olefin at reaction pressure, but below the critical temperature of the alcohol, and the olefin product is substantially in the gaseous phase. After the contacting step, the olefin containing gaseous phase is separated from the liquid phase. The invention also relates to catalytic processes such as a hydrolysis of an olefin to an alcohol, an esterification, a transesterification, a polymerization, an aldol condensation or an ester hydrolysis.